

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1231.003	Serial No.: 09/466,035
INFORMATION DISCLOSURE CITATION		Applicants: Salberg <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: 12/17/99	Group: to be assigned

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PP	AA	5,447,859	09/05/95	Prussak	435	239	
	AB	5,591,624	01/07/97	Barber <u>et al.</u>	435	240.2	
	AC	5,662,896	09/02/97	Barber <u>et al.</u>	424	93.2	
	AD	5,681,746	10/28/97	Bodner <u>et al.</u>	435	350	
	AE	5,693,522	12/02/97	Chada <u>et al.</u>	435	2.402	
	AF	5,716,613	02/10/98	Gruber <u>et al.</u>	424	93.2	
	AG	5,716,826	02/10/98	Gruber <u>et al.</u>	435	320.1	
	AH	5,716,832	02/10/98	Barber <u>et al.</u>	435	172.3	
	AI	4,599,230	07/08/86	Milich <u>et al.</u>	424	89	
	AJ	4,599,231	07/08/86	Milich <u>et al.</u>	424	89	
	AK	4,683,136	07/28/87	Milich <u>et al.</u>	424	89	
	AL	4,818,527	04/04/89	Thornton <u>et al.</u>	424	88	
	AM	4,882,145	11/21/89	Thornton <u>et al.</u>	424	88	
	AN	5,143,726	09/01/92	Thornton <u>et al.</u>	424	88	
	AO	5,166,320	11/24/92	Wu <u>et al.</u>	530	395	
PP	AP	5,532,143	07/02/96	Grosveld <u>et al.</u>	435	69.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans-Yes	lation No
PP	BA	WO 92/11028	07/09/92	PCT				
	BB	WO 94/24267	10/27/94	PCT				
	BC	WO 94/25601	11/10/94	PCT				
	BD	155,146 B1	09/18/85	Europe				
	BE	250,253 A2	12/23/87	Europe				
	BF	WO 91/17768	11/28/91	PCT				
PP	BG	WO 95/07994	03/23/95	PCT				
	BH	WO 95/30019	11/09/95	PCT				

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1231.003	Serial No.: 09/466,035
INFORMATION DISCLOSURE CITATION		Applicant: Sallberg <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: 12/17/99	Group: to be assigned

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

7P	CA	Ferrari <u>et al.</u> , "Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen" <u>J. Clin. Invest.</u> 88:214-222, 1991
	CB	Ott <u>et al.</u> , "Enhancement of Humoral Response Against Human Influenza Vaccine with the Simplest Submicron Oil/Water Emulsion Adjuvant MF59" <u>Vaccine</u> 13(16):1557-1562, 1995
	CC	Ott <u>et al.</u> , <u>Vaccine Design: The Subunit and Adjuvant Approach</u> , Plenum Press, New York, 1995, Chapter 10, "MF59, Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines," pp. 277-296
	CD	Valensi <u>et al.</u> , "Systemic Cytokine Profiles in BALB/c Mice Immunized with Trivalent Influenza Vaccine Containing MF59 Oil Emulsion and Other Advanced Adjuvants," <u>The Journal of Immunology</u> 153:4029-4039, 1994
	CE	Böhm <u>et al.</u> , "DNA Vector Constructs that Prime Hepatitis B Surface Antigen-Specific Cytotoxic T Lymphocyte and Antibody Responses in Mice after Intramuscular Injection" <u>J. Immunological Methods</u> 193:29-40, 1996
	CF	Hu <u>et al.</u> , "Immunization with HIV-1 gp160 Enhances HIV-Specific Immune Responses Elicited by Vaccinia-HIV Recombinant Virus," in 6 th International Conference on AIDS, San Francisco, California, 1990, Abstract No. Th.A.343
	CG	Li <u>et al.</u> , "Priming with Recombinant Influenza Virus Followed by Administration of Recombinant Vaccinia Virus Induces CD8+ T-cell-mediated Protective Immunity Against Malaria," <u>Proc. Natl. Acad. Sci. USA</u> 90:5214-5218, 1993
	CH	Rothel <u>et al.</u> , "Sequential Nucleic Acid and Recombinant Adenovirus Vaccination Induces Host-Protective Immune Responses Against Taenia Ovis Infection in Sheep," Database Medline File Server STN Karlsruhe Abstract Accession No. 97339359
	CI	Sallberg <u>et al.</u> , "Characterization of Humoral and CD4+ Cellular Responses after Genetic Immunization with Retroviral Vectors Expressing Different Forms of the Hepatitis B Virus Core and Antigens" <u>J. Virology</u> 71(7):5295-5303, 1997
	CJ	Lancki <u>et al.</u> , "Cytolytic T Lymphocytes: an Overview of Their Characteristics," <u>Biotherapy</u> 5(1):71-81, 1992
	CK	Bachmann <u>et al.</u> , "in vivo Versus in vitro Assays for Assessment of T- and B-Cell Function" <u>Current Opinion Immunology</u> 6(2):320-326, 1994
	CL	Mulligan, "The Basic Science of Gene Therapy" <u>Science</u> 260:926-932, May, 1993
	CM	Marshall, "Gene Therapy's Grown Pains," <u>Science</u> 269:1050-1055, August, 1995
	CN	Orkin <u>et al.</u> , "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," NIH Report and Recommendation, December 5, 1995
	CO	Verma <u>et al.</u> , "Gene Therapy-Promises, Problems, and Prospects," <u>Nature</u> 389:239-242, September, 1997
	CP	Davis <u>et al.</u> , "DNA-Mediated Immunization in Mice Induces a Potent MHC Class I-Restricted Cytotoxic Lymphocyte Response to the Hepatitis B Envelope Protein," <u>Human Gene Therapy</u> 6(11):1447-1456, November, 1995
	CQ	Milich <u>et al.</u> , "The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety," <u>Annals of the New York Academy of Sciences</u> , pages 187-201, May 31, 1995
	CR	Driver <u>et al.</u> , "Layered Amplification of Gene Expression With a DNA Gene Delivery System" <u>Annals of the New York Academy of Sciences</u> 772(DNA Vaccines):261-264, 1995
	CS	Xiang <u>et al.</u> , "Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines," <u>Immunity</u> 2:129-135, February, 1995
	CT	He <u>et al.</u> , "Costimulatory Protein B7-1 Enhances the Cytotoxic T Cell Response and Antibody Response to Hepatitis B Surface Antigen," <u>Proc. Natl. Acad. Sci.</u> 93(14):7274-7278, July, 1996
7P		

Examiner	<i>Rita Pung</i>	Date Considered	4/5/03
----------	------------------	-----------------	--------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.